Vol-Plus description, usages, side effects, indications, overdosage, supplying and lots more!

Vol-Plus

TRIGEN Laboratories, Inc.

Vol-PlusTablets

FULL PRESCRIBING INFORMATION: CONTENTS*




FULL PRESCRIBING INFORMATION

Rx Only

DESCRIPTION

Vol-Plus is an orally administered prescription vitamin for the dietary management of patients with nutritional deficiencies or are in need of nutritional supplementation. Vol-Plus is an oval, beige tablet with "TL519" debossed on one side.

Supplement Facts
Servings per Bottle: 500
Serving Size: 1 tablet
Each tablet contains:
% DV Adults & Children
4 Years or More
Folic Acid 1 mg 250%
Vitamin A (Input as vitamin A acetate and beta carotene) 4000 IU 80%
Vitamin C (ascorbic acid) 120 mg 200%
Calcium (calcium sulfate) 200 mg 20%
Iron (ferrous fumarate) 27 mg 150%
Vitamin D3 (cholecalciferol) 400 IU 100%
Vitamin E (dl-alpha-tocopheryl acetate) 22 mg 157%
Vitamin B1 (thiamine mononitrate) 1.84 mg 123%
Vitamin B2 (riboflavin) 3 mg 176%
Niacinamide (vitamin B3) 20 mg 100%
Vitamin B6 (pyridoxine HCl) 10 mg 500%
Vitamin B12 (cyanocobalamin) 12 mcg 200%
Zinc (zinc oxide) 25 mg 167%
Copper (cupric oxide) 2 mg 100%

Inactive Ingredients: Microcrystalline Cellulose, Beige Color Coating (Hydroxypropylmethyl Cellulose, Polyvinyl Alcohol, Titanium Dioxide, Polyethylene Glycol, Talc, FD&C Yellow #6 Lake, FD&C Blue #2 Lake), Pregelatinized Starch, Croscarmellose Sodium, Di Calcium Phosphate, Magnesium Stearate, Stearic Acid, Fumed Silica, Ascorbyl Palmitate.

INDICATIONS AND USAGE

Vol-Plus is indicated for the supplemental requirements of patients with nutritional deficiencies or are in need of nutritional supplementation.

CONTRAINDICATIONS

This product is contraindicated in patients with known hypersensitivity to any of the ingredients.

WARNING: Accidental overdose of iron-containing products is a leading cause of fatal poisoning in children under 6. KEEP THIS PRODUCT OUT OF REACH OF CHILDREN. In case of accidental overdose, call a doctor or poison control center immediately.

PRECAUTIONS

General

Folic acid, when prescribed as a single agent in doses above 0.1 mg daily, may obscure the detection of B12 deficiency (specifically, the administration of folic acid may reverse the hematological manifestations of B12 deficiency, including pernicious anemia, while not addressing the neurological manifestations). Reduced folates may be less likely than folic acid to mask vitamin B12 deficiency. Folate therapy alone is inadequate for the treatment of B12 deficiency.

PATIENT INFORMATION

Vol-Plus is a prescription vitamin for the use only under the direction and supervision of a licensed physician.

INTERACTIONS

Pyridoxine hydrochloride should not be given to patients receiving the drug levodopa, because the action of levodopa is antagonized by pyridoxine hydrochloride. However, pyridoxine hydrochloride may be used concurrently in patients receiving a preparation containing both carbidopa and levodopa.

Drugs which may interact with folate include:

  • Antiepileptic drugs (AED): The AED class including, but not limited to, phenytoin, carbamazepine, primidone, valproic acid, phenobarbital and lamotrigine have been shown to impair folate absorption and increase the metabolism of circulating folate. Additionally, concurrent use of folic acid has been associated with enhanced phenytoin metabolism, lowering the levels of this AED in the blood and allowing breakthrough seizures to occur.
  • Capecitabine: Folinic acid (5-formyltetrahydrofolate) may increase the toxicity of Capecitabine.
  • Cholestyramine: Reduces folic acid absorption and reduces serum folate levels.
  • Colestipol: Reduces folic acid absorption and reduces serum folate levels.
  • Cycloserine: Reduces folic acid absorption and reduces serum folate levels.
  • Dihydrofolate Reductase Inhibitors (DHFRI): DHFRIs block the conversion of folic acid to its active forms, and lower plasma and red blood cell folate levels. DHFRIs include aminopterin, methotrexate, pyrimethamine, triamterene, and trimethoprim.
  • Fluoxetine: Fluoxetine exerts a noncompetitive inhibition of the 5-methyltetrahydrofolate active transport in the intestine.
  • Isotretinoin: Reduced folate levels have occurred in some patients taking isotretinoin.
  • Nonsteroidal Anti-inflammatory Drugs (NSAIDs): NSAIDs have been shown to inhibit some folate dependent enzymes in laboratory experiments. NSAIDs include ibuprofen, naproxen, indomethacin and sulindac.
  • Oral Contraceptives: Serum folate levels may be depressed by oral contraceptive therapy.
  • Methylprednisolone: Reduced serum folate levels have been noted after treatment with methylprednisolone.
  • Pancreatic Enzymes: Reduced folate levels have occurred in some patients taking pancreatic extracts.
  • Pentamidine: Reduced folate levels have been seen with prolonged intravenous pentamidine.
  • Smoking and alcohol: Reduced serum folate levels have been noted.
  • Sulfasalazine: Inhibits the absorption and metabolism of folic acid.
  • Metformin treatment in patients with type 2 diabetes decreases serum folate.
  • Warfarin can produce significant impairment in folate status after a 6 - month therapy.

ADVERSE REACTIONS

Allergic sensitization has been reported following both oral and parenteral administration of folic acid, as well as possibly the use of other forms of folates - including reduced folates. Paresthesia, somnolence, nausea and headaches have been reported with pyridoxine hydrochloride. Mild transient diarrhea, polycythemia vera, itching, transitory exanthema and the feeling of swelling of the entire body have been associated with cyanocobalamin.

Ferrous Fumarate

Gastrointestinal disturbances (anorexia, nausea, diarrhea, constipation) occur occasionally, but are usually mild and subside with continuation of therapy and physician encouragement. Although, the absorption of iron is best when taken between meals, occasional gastrointestinal disturbances may be controlled giving Vol-Plus shortly after meals.

DOSAGE AND ADMINISTRATION

Before, during and after pregnancy, one tablet daily, or as prescribed by a physician.

HOW SUPPLIED

Vol-Plus is supplied as:
Bottles of 100 tablets: 13811-519-10
Bottles of 500 tablets: 13811-519-50

KEEP OUT OF REACH OF CHILDREN

Rx Only

Manufactured for:
TRIGEN Laboratories, Inc., Sayreville, NJ 08872
www.trigenlab.com

Rev. 04/13

PRINCIPAL DISPLAY PANEL - 500 Tablet Bottle Label

13811-519-50
Rx Only

Vol-Plus
Tablets

500 TABLETS

TRIGEN
LABORATORIES

PRINCIPAL DISPLAY PANEL - 500 Tablet Bottle Label

Vol-Plus

Folic Acid, ascorbic acid, thiamine mononitrate, riboflavin, pyridoxine Hydrochloride, cyanocobalamin, niacinamide, vitamin A acetate, .beta.-carotene, cholecalciferol, .alpha.-tocopherol acetate, dl-, cupric oxide, zinc oxide, ferrous fumarate, and calcium sulfate TABLET, COATED

Product Information

Product Type Dietary supplement Item Code (Source) NDC:13811-519
Route of Administration ORAL DEA Schedule

Active Ingredient/Active Moiety

Ingredient Name Basis of Strength Strength
FOLIC ACID FOLIC ACID 1 mg
ASCORBIC ACID ASCORBIC ACID 120 mg
THIAMINE MONONITRATE THIAMINE ION 1.84 mg
RIBOFLAVIN RIBOFLAVIN 3 mg
PYRIDOXINE HYDROCHLORIDE PYRIDOXINE 10 mg
Cyanocobalamin CYANOCOBALAMIN 12 ug
NIACINAMIDE 20 mg
VITAMIN A ACETATE 500 [iU]
.BETA.-CAROTENE .BETA.-CAROTENE 3500 [iU]
CHOLECALCIFEROL CHOLECALCIFEROL 400 [iU]
.ALPHA.-TOCOPHEROL ACETATE, DL- .ALPHA.-TOCOPHEROL, DL- 22 mg
CUPRIC OXIDE CUPRIC CATION 2 mg
Zinc Oxide Zinc oxide 25 mg
FERROUS FUMARATE FERROUS CATION 27 mg
CALCIUM SULFATE 200 mg

Inactive Ingredients

Ingredient Name Strength
cellulose, microcrystalline
HYPROMELLOSES
POLYVINYL ALCOHOL
titanium dioxide
POLYETHYLENE GLYCOLS
talc
FD&C YELLOW NO. 6
FD&C BLUE NO. 2
ACACIA
POVIDONE K30
CALCIUM PHOSPHATE, DIBASIC, ANHYDROUS
CROSCARMELLOSE SODIUM
Potassium Citrate Anhydrous
CITRIC ACID MONOHYDRATE
MAGNESIUM STEARATE
STEARIC ACID
ASCORBYL PALMITATE

Product Characteristics

Color Size Imprint Code Shape
WHITE (beige) 22 mm TL519 OVAL

Packaging

# Item Code Package Description Marketing Start Date Marketing End Date
1 NDC:13811-519-10 100 in 1 BOTTLE, PLASTIC
2 NDC:13811-519-50 500 in 1 BOTTLE, PLASTIC

Marketing Information

Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
2010-06-01


PLEASE, BE CAREFUL!
Be sure to consult your doctor before taking any medication!
Copyright © 2014. drugs-library.com. All rights reserved. Information on drugs-library.com is provided for educational purposes only and is not to be used for medical advice, diagnosis or treatment.
Support info@drugs-library.com.